{"nct_id":"NCT05424380","title":"A Phase 1, Open Label Study of Intravenous GSK3745417 to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Determine RP2D & Schedule in Participants With Relapsed or Refractory Myeloid Malignancies Including AML and HR MDS","status":"TERMINATED","status_verified_date":"2025-02","start_date":"2022-09-20","start_date_type":"ACTUAL","primary_completion_date":"2024-03-04","primary_completion_date_type":"ACTUAL","completion_date":"2024-03-04","completion_date_type":"ACTUAL","phases":["PHASE1"],"tickers":["GSK"]}